GCP
HRTX icon

GSA Capital Partners’s Heron Therapeutics HRTX Stock Holding History

GSA Capital Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$445K Buy
1,042,892
+937,828
+893% +$752K 0.03% 1074
2026
Q1 		$84K Sell
105,064
-30,025
-22% -$34.8K 0.01% 1573
2025
Q4 		$176K Buy
135,089
+34,908
+35% +$43.1K 0.02% 1444
2025
Q3 		$126K Sell
100,181
-197,140
-66% -$313K 0.01% 1505
2025
Q2 		$615K Buy
+297,321
New +$607K 0.04% 773
2024
Q4 		– Sell
-512,736
Closed -$1.02M – 1777
2024
Q3 		$1.02M Buy
512,736
+79,680
+18% +$190K 0.08% 455
2024
Q2 		$1.52M Buy
433,056
+153,357
+55% +$471K 0.11% 272
2024
Q1 		$775K Sell
279,699
-59,749
-18% -$150K 0.06% 615
2023
Q4 		$577K Buy
+339,448
New +$374K 0.05% 700
2023
Q2 		– Sell
-64,528
Closed -$97K – 1688
2023
Q1 		$97K Sell
64,528
-52,046
-45% -$130K 0.01% 1366
2022
Q4 		$291K Buy
116,574
+30,115
+35% +$97K 0.04% 946
2022
Q3 		$365K Sell
86,459
-114,965
-57% -$450K 0.05% 804
2022
Q2 		$562K Buy
201,424
+53,152
+36% +$213K 0.08% 427
2022
Q1 		$848K Buy
148,272
+113,898
+331% +$833K 0.11% 243
2021
Q4 		$314K Sell
34,374
-2,068
-6% -$21.1K 0.04% 897
2021
Q3 		$390K Sell
36,442
-23,651
-39% -$288K 0.04% 851
2021
Q2 		$933K Buy
60,093
+26,724
+80% +$425K 0.11% 285
2021
Q1 		$541K Buy
+33,369
New +$595K 0.09% 309
2020
Q4 		– Sell
-42,177
Closed -$625K – 1378
2020
Q3 		$625K Buy
+42,177
New +$658K 0.1% 275
2020
Q2 		– Sell
-40,459
Closed -$475K – 832
2020
Q1 		$475K Buy
40,459
+12,900
+47% +$242K 0.12% 190
2019
Q4 		$648K Buy
+27,559
New +$610K 0.08% 469

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

GSA Capital Partners's HRTX Position: Q2 2026 in Review

GSA Capital Partners increased its Heron Therapeutics (HRTX) stake by 893% in Q2 2026, buying an estimated $752K and bringing the position to 1,042,892 shares worth $445K. The position accounts for 0.03% of the portfolio, ranked #1074.

GSA Capital Partners first reported a position in HRTX in Q4 2019 and has held it in 21 quarters since. The position peaked at $1.52M in Q2 2024. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • GSA Capital Partners held 1,042,892 shares of Heron Therapeutics worth $445K as of Q2 2026.
  • GSA Capital Partners bought 937,828 Heron Therapeutics shares in Q2 2026, an estimated $752K.
  • Heron Therapeutics made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #1074 holding.
  • GSA Capital Partners first reported a position in Heron Therapeutics in Q4 2019 and has held it in 21 quarters since.
  • GSA Capital Partners's Heron Therapeutics position peaked at $1.52M in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.